June 2026—Artera has been granted the CE mark under the European Union in vitro diagnostic regulation for its ArteraAI Prostate Biopsy and ArteraAI Breast Cancer assays. The prostate biopsy assay helps predict the likelihood that prostate cancer will spread and the risk of mortality and helps determine whether a patient is likely to benefit from adding short‑term hormone therapy to their treatment. The ArteraAI Breast Cancer assay builds on Artera’s multimodal AI platform, which has been clinically validated in patient cohorts worldwide and presented in leading scientific forums. Both tests leverage the use of digitized histopathology images and patient clinical variables to determine cancer aggressiveness and potential treatment benefits.
Artera, 650-239-7018